Project Grant HT94252410837
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$906K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This $1,038,931 federal Project Grant was awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant funds research conducted by The Medical University of South Carolina (MUSC) to study SETD2 deficiency and its potential to increase sensitivity to BCL-XL inhibition, which may lead to new treatment approaches. The award has a performance period from September 30, 2024 to September 29, 2028. MUSC, a public university and major...
The Defense Health Agency awarded a $755,001 Project Grant to The Medical University of South Carolina (MUSC) under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, running from July 1, 2023 to June 30, 2026, supports research on microsomal glutathione transferase as a new target in melanotic melanoma. As a public institution of higher education, MUSC conducts biomedical research and provides healthcare services, with a mission to preserve and optimize...
The Medical University of South Carolina (MUSC) was awarded a $1,503,880 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research into the function of the ARIH1 gene in epithelial-mesenchymal transition (EMT) and tumorigenesis. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
This $1,339,689 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a study to identify and characterize metastasis-driving tumor cell subpopulations in localized stage III clear cell renal cell carcinoma. The research will be conducted by The Feinstein Institutes for Medical Research, a leading non-profit medical research organization, over a 4-year period from August 1, 2024 to July 31, 2028. The study aims to...
The Defense Health Agency awarded a $1,086,750.00 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the project "TARGETING ENVIRONMENTAL FERROPTOSIS PROTECTION AS NOVEL THERAPEUTIC STRATEGY FOR METASTATIC RENAL CELL CARCINOMA" and will be completed by Aug 31, 2026. The project aims to research novel therapeutic strategies for metastatic renal cell carcinoma by targeting environmental ferroptosis protection.
The federal Project Grant award, totaling $1,944,610.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization located in New York, to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. The research aims to transform healthcare for...
The Department of the Army Medical Command awarded Duke University a $1,932,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2022 through August 31, 2025. The grant funds research to define cellular and genetic factors for renal cell carcinoma subtypes. Through this award, Duke University researchers will investigate medical solutions for kidney cancer on the cellular and genetic levels to advance understanding,...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
The federal Project Grant award of $564,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by The Institute For Cancer Research to explore the role of MUL1 in prostate tumorigenesis. The award, with a performance period from May 1, 2025 to April 30, 2027, will fund sophisticated cancer research focused on developing innovative approaches to prostate cancer prevention, diagnosis, and treatment. The Institute...